Related Experiment Video
Updated: Feb 13, 2026

Double Direct Injection of Blood into the Cisterna Magna as a Model of Subarachnoid Hemorrhage
Published on: August 30, 2020
A consortium for purchase of blood products directed by physicians
L M Aledort1, R A Lipton, M Hilgartner
1Mt. Sinai Medical Center, New York.
Insights
Physicians formed a consortium to lower clotting-factor concentrate costs for hemophilia treatment. This collaborative purchasing strategy achieved significant price reductions and savings for patients and hospitals.
Area of Science:
- Hematology
- Health Economics
- Healthcare Management
Background:
- Clotting-factor therapy represents a substantial expense in comprehensive hemophilia care.
- Managing the high cost of clotting-factor concentrates is crucial for patient access and healthcare sustainability.
Purpose of the Study:
- To evaluate the effectiveness of a physician-led consortium for the centralized purchasing and regional distribution of clotting-factor concentrates.
- To determine the impact of this model on pricing, cost savings, and overall efficiency in hemophilia treatment.
Main Methods:
- Formation of a physician consortium in New York for collaborative purchasing of clotting-factor concentrates.
- Implementation of a bidding formula to secure the lowest prices for quality products while ensuring supplier participation.
- Establishment of a central distribution system for regional delivery to participating hospitals.
Main Results:
- The consortium successfully maintained and, in some cases, reduced the prices of clotting-factor concentrates annually.
- Estimated regional savings exceeded $750,000 for an anticipated purchase of 60 million units of clotting factors VIII and IX.
- Centralized distribution led to additional cost reductions for participating hospitals, offering competitive prices nationwide.
Conclusions:
- A physician-directed regional purchasing consortium can effectively lower the cost of expensive medical products like clotting-factor concentrates.
- This collaborative model offers significant financial benefits to patients, third-party payers, and healthcare institutions.
- The consortium's success suggests a transferable strategy for managing costs in other clinical areas requiring high-cost therapies.
Abstract:
Clotting-factor therapy is a costly part of comprehensive hemophilia treatment. Physicians treating patients with hemophilia in New York formed a consortium for the purchasing and regional distribution of clotting-factor concentrates. Concentrates are centrally purchased based on a bidding formula aimed at obtaining the lowest price for quality product while guaranteeing all suppliers continued involvement in a large market area. The consortium has successfully maintained, and, in instances, lowered prices each year. Estimated regional savings this year are more than $750,000 for an anticipated purchase of approximately 60,00,000 units of clotting-factors VIII and IX. Central distribution has additionally lowered costs to participating hospitals. The consortium is able to provide patients and third-party payers with some of the lowest prices for clotting-factor concentrates in the United States. A physician-directed regional approach to purchasing costly medical products might be applied to other areas of clinical medicine.
More Related Videos
09:04A Direct, Early Stage Guanidinylation Protocol for the Synthesis of Complex Aminoguanidine-containing Natural Products
Published on: September 9, 2016
12:40Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Related Concept Videos
Directing Effect of Substituents: meta-Directing Groups
Directing Effect of Substituents: ortho–para-Directing Groups
Scalar Product (Dot Product)
The scalar product of two vectors is obtained by multiplying...
Vector Product (Cross Product)
Consider the cross product of two vectors. Imagine rotating the first vector about...
Directional Terms
Directional Relays